GeoVax Labs, Inc. GOVX PHARMA

Q: What is the current share price of GeoVax Labs, Inc. (GOVX)?

As of 2026-09-19 21:16 PDT, GeoVax Labs, Inc. (GOVX) trades at $0.47 on NasdaqCM. Its 52-week range is $0.47 to $19.58.

Q: What is the market capitalisation of GOVX?

GeoVax Labs, Inc. (GOVX) has a market capitalisation of $4.27M on NasdaqCM.

Q: What is the P/E ratio of GOVX?

GOVX trades at a trailing price-to-earnings (P/E) ratio of -0.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.49.

Q: Is GOVX a good stock to buy?

This page provides a data-driven analysis of GeoVax Labs, Inc. (GOVX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.geovax.com

Company Profile ↓

$0.47

-97.47% 1Y

Mkt Cap$4.27M

P/E-0.08

P/B1.49

52W High$19.58

52W Low$0.47

Book Value$0.24

EPS (TTM)$-5.62

Company Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 13.0% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Recent Developments

Dec 2025 Revenue of $2.49M (-37.1% YoY); net profit $-21.46M.
Trailing 12 Months Year-on-year growth — revenue -37.1%.
5-Year Trend Long-term compounding — revenue CAGR 13.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	13.00%
1 Year:	-37.06%

Stock Price Performance

1 Year:	-97.47%
6 Months:	-75.62%
3 Months:	-65.07%
1 Month:	-39.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 0% of range

$0.47 $19.58

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)29.08 · Oversold

Price Performance

1M-39.22%

3M-65.07%

6M-75.62%

1Y-97.47%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 13.0% over 5 years.

CONS

Trading 97.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.08

Industry PE

24.83

Forward P/E

-0.55

PEG Ratio

Book Value

$0.24

Price to Book

1.49

P/S

inf

EV/EBITDA

0.01

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

13.00%

Profit 5Y

Revenue (YoY)

-37.06%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

EPS (TTM)

$-5.62

Balance Sheet & Liquidity

Debt/Equity

0.18

Quick Ratio

1.16

Current Ratio

1.54

Debt

$323.14K

Total Assets

$4.64M

Current Assets

Working Capital

Ownership

Promoter Holding

0.03%

Chg in Prom Hold

-0.01%

FII / Inst Holding

9.77%

Chg in FII Hold

-2.29%

Financial Snapshot

Enterprise Value

$4.27M

Total Revenue (TTM)

EBITDA

$-20.47M

Free Cash Flow

$-10.82M

Operating Cash Flow

$-18.37M

Shares Outstanding

9.09M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GOVX GeoVax Labs, Inc. PHARMA	0.47	-0.08	$4.27M	0.00%	-	-	13.00%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	295.74K	352.14K	247.99K	221.30K	93.27K	349.34K	364.23K	209.94K	333.21K	715.98K	440.60K	415.46K	110.42K	79.71K	30.41K	81.53K	0	0	0	0	0	0	300.68K	2.79M	1.64M	852.28K	0	0	0
Operating Income	-617.32K	-680.62K	-515.23K	-	-701.65K	-678.07K	-621.32K	-	-1.30M	-576.11K	-464.54K	-548.73K	-518.15K	-590.35K	-622.92K	-638.13K	-667.33K	-701.55K	-653.94K	-425.94K	-595.30K	-448.11K	-436.31K	-1.56M	-1.49M	-1.95M	-2.43M	-2.24M	-3.97M	-4.27M	-6.18M	-8.60M	-5.88M	-5.06M	-5.85M	-5.41M	-5.42M	-6.37M	-5.27M	-4.44M
Net Income	-615.92K	-679.54K	-514.51K	-923.59K	-700.45K	-676.20K	-619.90K	-692.73K	-1.30M	-575.84K	-464.20K	-548.34K	-516.88K	-588.76K	-621.81K	-637.04K	-666.89K	-701.45K	-654.15K	-424.43K	-595.69K	-455.20K	-570.65K	-1.56M	-1.31M	-1.95M	-2.43M	-2.24M	-3.97M	-4.04M	-5.93M	-8.41M	-5.85M	-5.06M	-5.82M	-5.36M	-5.37M	-6.32M	-5.26M	-4.43M
R&D Expense	402.86K	516.20K	425.50K	-	403.63K	384.65K	378.52K	-	438.00K	397.58K	683.94K	551.79K	518.10K	498.20K	486.99K	372.20K	557.70K	555.72K	451.23K	467.67K	808.94K	461.42K	416.76K	602.78K	832.84K	1.22M	1.33M	1.31M	2.72M	2.82M	4.72M	6.95M	4.43M	4.28M	7.40M	5.35M	4.73M	5.04M	3.90M	3.11M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	828.92K	1.08M	963.20K	1.18M	1.82M	385.50K	81.53K	0	3.95M	2.49M
Operating Income	-	-	-	-	-	-	-	-3.32M	-2.77M	-2.35M	-2.14M	-2.29M	-2.74M	-2.69M	-3.27M	-2.17M	-2.56M	-2.37M	-2.82M	-18.75M	-14.03M	-26.74M	-25.14M	-21.64M
Net Income	-618.14K	-947.80K	-2.35M	-1.61M	-584.17K	-4.24M	-3.73M	-3.28M	-2.75M	-2.35M	-2.14M	-2.28M	-2.73M	-2.69M	-3.27M	-2.17M	-2.56M	-2.37M	-2.96M	-18.57M	-14.02M	-25.97M	-24.99M	-21.46M
R&D Expense	-	-	-	-	-	-	-	4.07M	4.79M	4.28M	3.04M	2.91M	1.81M	1.69M	1.97M	2.02M	1.88M	1.91M	2.44M	15.55M	9.12M	20.72M	23.71M	18.12M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	2.36M	1.65M	1.48M	2.84M	1.33M	1.33M	610.22K	490.24K	642.06K	468.88K	10.39M	11.80M	31.35M	9.28M	8.16M	6.34M
Total Equity	-170.58K	-639.39K	872.41K	-389.50K	-500.58K	2.20M	2.65M	2.71M	3.74M	1.84M	703.61K	1.15M	2.53M	1.15M	1.20M	240.37K	-321.06K	-1.02M	-1.57M	9.57M	4.36M	26.60M	5.76M	5.05M	3.83M
Cash & Equivalents	-	-	-	-	-	-	-	2.19M	3.52M	1.08M	1.17M	1.04M	2.51M	1.10M	1.06M	454.03K	312.73K	259.70K	283.34K	9.88M	11.42M	27.61M	6.45M	5.51M	3.09M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	811.29K	1.66M	2.04M	825.05K	7.44M	4.75M	-	3.11M	2.52M
Current Liabilities	-	-	-	-	-	-	-	-	-	521.61K	941.53K	327.04K	312.35K	187.02K	126.99K	369.85K	811.29K	1.62M	2.02M	810.31K	5.44M	4.75M	3.52M	3.11M	1.94M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.43M	-2.44M	-303.62K	-2.44M	-1.69M	-2.25M	-2.71M	-1.95M	-1.69M	-1.54M	-1.40M	-2.75M	-11.20M	-19.03M	-25.17M	-24.68M	-21.47M
Investing Cash Flow	-270.25K	874	-11.90K	-	-86.60K	-35.50K	-15.85K	-	-4.35K	-	-7.61K	-156.79K	-47.72K	-134.26K	-48.95K	-20.65K	-27.61K
Financing Cash Flow	3.02M	-430.40K	404.41K	2.31M	3.26M	873.40K	2.68M	1.34M	1.55M	1.49M	1.43M	12.51M	12.78M	35.35M	4.06M	23.75M	19.08M
Capital Expenditure	-270.25K	-4.71K	-11.90K	-	-86.60K	-35.50K	-15.85K	-	-4.35K	-	-7.61K	-156.79K	-47.72K	-134.26K	-48.95K	-20.65K	-27.61K
Free Cash Flow	-1.70M	-2.44M	-315.52K	-	-1.78M	-2.29M	-2.72M	-	-1.69M	-	-1.41M	-2.91M	-11.24M	-19.16M	-25.22M	-24.70M	-21.50M

Ratios (Annual)

Figures in %.

Metric	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-394.9%	-202.2%	-266.1%	-201.8%	-154.5%	-4,862.7%	-17,207.5%	-	-635.8%	-869.3%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-394.7%	-201.8%	-265.8%	-201.6%	-162.2%	-4,817.2%	-17,198.3%	-	-632.0%	-862.3%
ROE %	96.7%	-108.6%	603.8%	321.8%	-26.5%	-160.2%	-137.6%	-87.7%	-149.6%	-333.5%	-185.5%	-90.4%	-238.5%	-223.3%	-1,361.1%	675.9%	250.4%	150.6%	-30.9%	-425.8%	-52.7%	-450.6%	-495.0%	-561.2%
ROCE %	-	-	-	-	-	-	-	-	-150.9%	-333.9%	-185.8%	-90.6%	-238.8%	-223.7%	-1,361.8%	677.3%	260.8%	153.3%	-29.4%	-294.7%	-52.7%	-464.0%	-498.1%	-491.2%

Shareholding Pattern

Insiders

0.03%

Institutions

9.77%

Public Float

9.78%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Jane Street Group, LLC	3.47%	315.27K	$112.52K
2	HRT Financial LP	1.39%	126.70K	$45.22K
3	Geode Capital Management, LLC	0.23%	21.11K	$7.53K
4	Two Sigma Securities, LLC	0.12%	10.68K	$3.81K
5	Vanguard Fiduciary Trust Co	0.06%	5.07K	$1.81K
6	Tower Research Capital LLC (TRC)	0.04%	3.50K	$1.25K
7	Vanguard Capital Management LLC	0.04%	3.22K	$1.15K
8	SBI Securities Co., Ltd.	0.03%	2.59K	$923
9	Morgan Stanley	0.02%	2.00K	$714
10	Jones Financial Companies, L.L.L.P.	0.01%	1.00K	$356

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GOVX

Google News Sat, 27 Jun 2026

GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPTXpxN1dVUFpHS1loSC1HNGxLbERVV1l5QVR5UU5xa0dYQUhaVUNzanZQcE1ia1haMzFER2JNR0w0Q25nTDRsaFR6WHBvY0Vwb0g5d3UwNmJqMFgzUHVSZ0o3WTI1cmc0T3FDR041SDlvN3FfbTRrd0I4Tm9CNkYwc3VWZ0gtSFk3R3J0VG…

Google News Mon, 07 Sep 2026

S&P 500, Dow, Nasdaq Futures Edge Lower As Tech Selloff Overshadows Iran Deal Hopes: D, NEE, DUOT, NKE, TE, Stocks In Focus - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPLWpUNzliMGNiVmxHdTBKZjJSUjh3YS16ZHhnQjlEVEZxakxUMk9sdjdmbEJlY1hHSnFvWUowcmRHczhxdHV6VE9hOTg5dUhkLUxyQV9mUlBUZFNqVVlIX0ZDemNSdjB0UjlBQS1XSFlDT1l3MDNOQlpWRU1DdGx4d2VUbWpKSUlvdVotR3…

Google News Mon, 27 Jul 2026

GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings | GOVX Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPM0R0enNNcGk1WFlSdUdyamh2T1RHQzhLWHJudG5RdlFWS0x5bUFvWVJINm1rS0t5dHR2ZXR1S3J0eS1ieW84b1h1WUx0OUZ1dVY0R2d0OGFDdkROUWcwUzlZRXRrTjhvUWdjUzZOeVN2aVBBdDdLcTdkX1hRY2xST0N3V1JQS2w5bzdrSA…

Google News Fri, 12 Jun 2026

Should I buy GeoVax Labs (GOVX) - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBlRU1RTm9kWWV4bWs1RGpOem1nWnVUNF9aMDVVSTNYcGwwQ3d2eDhYWVB5UVNBMXdTMU5BaFBXbEtUZjhCaVZjODVzV0hVb2JQS1FERjJoQkpWTmZKRmRPbzY2T1IzWlVJRl80MQ?oc=5" target="_blank">Should I buy GeoVax L…

Google News ue, 26 May 2026

GOVX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9HNE11M0VHQ1RvM19TQWczOGU2RlE4MEZjTXdKU0dsUlZCdjNFM2t0U2tZd2FQYnhfSlQ0MzRtTHltekUxb0E?oc=5" target="_blank">GOVX</a>  <font color="#6f6f6f">Finviz</font>…

Google News ue, 19 May 2026

Why Is GeoVax Labs Stock Falling Tuesday? - Benzinga

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPcmZFNllrOEd0T2l5dEJaSG0wandOc0EzaEloekRENEhsUFNsS25JbWx5Ti12MlhmMWgxVmI3T0pXTjZmcmRkODhObFhnZU5OazZaQnFDUmIzOXdBZHNST19QdTVmUXVNNmdQT2h2TVp3NEhKM0ZXZk1mWGpfQ2xtR2hrMXlIeXF3dkdRWD…

GOVX — Frequently Asked Questions

What is the current share price of GeoVax Labs, Inc. (GOVX)?

As of 2026-09-19 21:16 PDT, GeoVax Labs, Inc. (GOVX) trades at $0.47 on NasdaqCM. Its 52-week range is $0.47 to $19.58.

What is the market capitalisation of GOVX?

GeoVax Labs, Inc. (GOVX) has a market capitalisation of $4.27M on NasdaqCM.

What is the P/E ratio of GOVX?

GOVX trades at a trailing price-to-earnings (P/E) ratio of -0.08. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.49.

Is GOVX a good stock to buy?

This page provides a data-driven analysis of GeoVax Labs, Inc. (GOVX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

GeoVax Labs, Inc. GOVX PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - finance.yahoo.com

S&P 500, Dow, Nasdaq Futures Edge Lower As Tech Selloff Overshadows Iran Deal Hopes: D, NEE, DUOT, NKE, TE, Stocks In Focus - Stocktwits

GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings | GOVX Stock News - Quiver Quantitative

Should I buy GeoVax Labs (GOVX) - Zacks Investment Research

GOVX - Finviz

Why Is GeoVax Labs Stock Falling Tuesday? - Benzinga

GOVX — Frequently Asked Questions

What is the current share price of GeoVax Labs, Inc. (GOVX)?

What is the market capitalisation of GOVX?

What is the P/E ratio of GOVX?

Is GOVX a good stock to buy?

Explore More